ABSTRACr A technique for the direct labelling of ipratropium bromide with bromine-77, with reconstitution of the drug in a metered dose inhaler so as to be identical to the commercial product, was used to study drug deposition patterns in seven normal subjects and seven patients with chronic bronchitis (mean FEV, 32% (SD 12-2%) predicted normal). The gamma camera image of the thorax was divided into a middle zone-the mediastinal zone-and the lung itself into a central zone comprising its medial third and a peripheal zone, the lateral two thirds. Measurements after 10 inhalations of labelled ipratropium bromide showed similar results for the two groups of subjects. The total lung dose inhaled was 11'2% of 203 ,ug and 11X7% of 186 ,ug in the normal subjects and the patients respectively. In contrast to the deposition patterns seen in aerosol studies using steady state inhalation methods, there was no difference in deposition pattern-that is, the distribution between the central and the peripheral lung zones-between the normal subjects and the patients with airways obstruction. with the y emitter bromine-77(77Br). We give a brief outline of the technique and its quality control, followed by the results of drug deposition studies performed with a gamma camera in a group of normal subjects and patients with chronic bronchitis.
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Methods

THE DRUG AND ITS ADMINISTRATION
The methods for labelling ipratropium bromide with "Br and incorporating it into a reconstituted metered dose aerosol have been described fully elsewhere.3 Briefly, we developed a system to label the drug, remill it into particles of the required size range, and add it to an accurately dispensed chlorofluorocarbon propellant mixture. Quality control procedures were also necessary to ensure compatibility with the commercial product. These procedures included ultraviolet colorimetry on canisters of both unlabelled and the labelled reconstituted drug and a final comparison of these was made with estimation of drug release based on loss of radioactivity. All reconstituted aerosols for clinical use were within the manufacturer's specification for the product. 432 Direct labelling of ipratropium bromide aerosol and its deposition pattern To obtain a statistically acceptable gamma camera image each subject was required to take 10 inhalations from the metered dose inhaler. The method of administration adopted was the one used most commonly in clinical practice. After exhalation to residual volume, the inhaler was actuated while the subject began a fast, deep inhalation, with the lips around the plastic mouthpiece, to total lung capacity; the breath was held for five seconds. Expired air was collected in a Douglas bag. The subject was allowed to inhale at his preferred flow rate and frequency but the procedure was completed within four minutes. After inhalation, the subject gargled and spat out the mouthful of water, which was collected for counting the radioactivity, and then swallowed two further mouthfuls of water to clear the oesophagus of radioactivity. Radioactivity deposited on the actuator was also counted.
IMAGING
The subject was seated in front of the gamma camera so that the lung field was central within the field of view. Both anteroposterior and posteroanterior "Br images were obtained to permit subsequent quantitation of regional lung deposition, a geometric mean calculation being used. In vivo calibration factors to calculate this regional deposition were obtained on the basis of "Br activities in variable thickness tissue equivalent (water) phantoms. This related the count rate from the canister in air at a fixed distance from the camera to the equivalent count rate in a given thickness of tissue. Each subject's chest thickness was measured to effect this correction. Data were recorded into a 64 x 64 computer matrix with an imposed count limit of 50 K for the anteroposterior view. This number of counts was considered to be statistically acceptable for quantitation and the accumulation time short enough to avoid significant changes in the tracer distribution. The posteroanterior image was recorded for the same time as the anteroposterior image. After each "Br image and without moving the patient, a rapid transmission scan was obtained, a cobalt-57 (57Go) flood field source being used. This gave an outline of the lungs and enabled an arbitrary division into a "peripheral zone" comprising the lateral two thirds of each lung and a "central zone." The region between the lungs was designated the "mediastinal zone" and comprised trachea, main bronchi, and oesophagus. Finally, a background image was accumulated for the same length of time so that lung regions selected for analysis could be corrected for background radioactivity.
SUBJECTS
Two groups of subjects were studied, seven normal and seven with chronic obstructive bronchitis. Pulmonary function studies before the start of the inhalation procedures were performed with a dry bellows spirometer with a microprocessor output (Oldelft "Floop") and included the forced expiratory volume in one second (FEV,), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and maximal expiratory flow at 50% of vital capacity (V50). Predicted normal values were taken from
Cotes.4 Results
The personal details of the two groups are summarised in table 1. The patients were older than the normal subjects and had moderately severe airways obstruction.
The fate of 10 puffs of ipratropium bromide is summarised in table 2. The mean total doses inhaled were similar in the two groups and close to 200 ,ug. An additional 5% of the drug released from the canister remained in the actuator. The distribution of ipratropium bromide was also similar in the two Table 3 Distribution of 10 puffs ofipratropium bromide within the lungs ofnormal subjects and patients with chronic bronchitis (means with standard deviations in parentheses) Mediastinal zone (to) 37-7 45J14 38-2 (4-3 ,7 groups; most of the drug was either deposited in the mouth or swallowed-180 ,ug in the normal subjects and 164 ,ug in the patients. The mean dose reaching the lung (including the mediastinal zone) was 11-2% and 11-7% respectively. The cause of this difference is not certain. Probably the predominantly central deposition is due to the high ejection velocity of the drug and also the proximity of the metered dose inhaler to the mouth, which does not allow time for sufficient decrease in size by evaporation of the chlorofluorocarbon pellets released at actuation. This may explain why intrathoracic deposition is increased with a tube device or a spacer attachment,78 so that lung function is better than when the metered dose inhaler is used alone.'" In the study of Newman et aP 10 patients with airways obstruction had a mean whole lung deposition of 7-8% of inhaled Teflon labelled particles, which increased to 13-0% when a 22 cm long spacer cone was used.
We have shown that pharmacokinetic methods' and indirect methods of estimating the dose of aerosol entering the lungs2 from a metered dose inhaler are sufficiently accurate. For direct labelling
